BOSTON--(BUSINESS WIRE)--Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced the appointment of Paul Herbert to Senior Vice President of Pharmaceutical Development.
“Paul is a seasoned leader with a significant track record of accomplishment in the life sciences industry,” said Chase Coffman, co-founder and CEO, Elektrofi. “His technical and operational experience will help us realize critical milestones, and his insights and guidance will be important to our business as we work towards the clinic next year.”
Mr. Herbert is a highly experienced senior executive with a proven track record in the pharmaceutical industry. Prior to joining Elektrofi, Mr. Herbert served as Vice President of Process Development & Engineering at Alkermes, where he led teams of up to 100 individuals in all aspects of drug product operations, including sterile process design, regulatory documentation, CDMO/CMO management, and clinical manufacturing. An industry veteran with approximately 30 years of experience in pharmaceutical development, Mr. Herbert is a pioneer and leading expert in product development and manufacturing for particle-based products and has led the development of twelve processes to NDA submission.
“It’s a pleasure to welcome Paul to the Elektrofi team. His expertise in process development and manufacturing strengthens Elektrofi’s capabilities and commitment to their partners ultimately to patients with innovative drug products ” said Charles Cooney, member of Elektrofi’s Board of Directors.
Paul Herbert commented, “I’m excited to join Elektrofi and be part of a team working on technology with the potential to create significant change in the delivery of biologics.”
About Elektrofi
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform aims to enable stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company’s founding team of MIT engineers and scientists are shaping the future of biologics delivery. Visit www.elektrofi.com for more information.
